{"protocolSection": {"identificationModule": {"nctId": "NCT03347279", "orgStudyIdInfo": {"id": "D5180C00007"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma", "officialTitle": "A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)", "acronym": "NAVIGATOR"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-11-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-09-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-11-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-11-09", "studyFirstSubmitQcDate": "2017-11-17", "studyFirstPostDateStruct": {"date": "2017-11-20", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-09-07", "resultsFirstSubmitQcDate": "2021-10-29", "resultsFirstPostDateStruct": {"date": "2021-11-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-29", "lastUpdatePostDateStruct": {"date": "2021-11-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Amgen", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma", "detailedDescription": "This is a multicentre, randomized, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 1060 subjects will be randomized globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, Uncontrolled Asthma, Severe Uncontrolled Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "maskingDescription": "Double-Blind", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1061, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tezepelumab", "type": "EXPERIMENTAL", "description": "Tezepelumab: Tezepelumab subcutaneous injection", "interventionNames": ["Biological: Experimental: Tezepelumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo: Placebo subcutaneous injection", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Experimental: Tezepelumab", "description": "Tezepelumab subcutaneous injection", "armGroupLabels": ["Tezepelumab"], "otherNames": ["Tezepelumab"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo subcutaneous injection", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma", "description": "The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)", "timeFrame": "From randomisation to Study Week 52."}, {"measure": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL", "description": "The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. This analysis is based on subjects with baseline eosinophils \\< 300 cells/uL", "timeFrame": "From randomisation to Study Week 52."}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline at Week 52 in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) (L) (Key Secondary Endpoint)", "description": "Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline at Week 52 in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score (Key Secondary Endpoint)", "description": "Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline at Week 52 in Asthma Control Questionnaire-6(ACQ-6) (Key Secondary Endpoint)", "description": "Change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting \u03b22-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline at Week 52 in Asthma Symptom Diary (Key Secondary Endpoint)", "description": "Mean change from baseline at Week 52 in Asthma Symptom Diary. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Time to First Asthma Exacerbation", "description": "Time to first occurrence of asthma exacerbation post-randomisation, presented as number of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline at Week 52 in Clinic Fractional Exhaled Nitric Oxide (FeNO) (Ppb)", "description": "Mean change from baseline at Study Week 52 in FeNO (ppb) measured at site", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52", "description": "Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \\[number of night nebulizer times\\] + number of daytime inhaler puffs + 2 x \\[number of day nebulizer times\\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline in Work Productivity Loss Due to Asthma at Week 52", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline in Class Productivity Loss Due to Asthma at Week 52", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Class productivity loss is derived by sum of percentage of missed class hours due to asthma and product of percentage of actual hours in class times degree of asthma affecting productivity while in class. Percentage of missed hours in class due to asthma is calculated by number of hours in class missed due to asthma divided by total number of hours in class missed plus number of hours actually in class.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Activity Impairment at Week 52", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Activity impairment is the degree health affected regular activities (other than work or class) rated from 0 to 10, with 0 meaning no effect, divided by 10, and then expressed as a percentage.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Pharmacokinetics of Tezepelumab", "description": "Mean serum trough PK concentrations taken pre-dose at each visit", "timeFrame": "Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, Week 64"}, {"measure": "Mean Change From Baseline at Week 52 in EQ-5D-5L VAS", "description": "Mean change from baseline at Study Week 52 in EQ-5D-5L VAS. EQ-5D-5L visual analogue scale (VAS) allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.", "timeFrame": "At Study Week 52"}, {"measure": "Clinicians Global Impression of Change at Week 52", "description": "CGIC (Clinical global impression of change) is an overall evaluation of response to treatment, conducted by investigator using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse)", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Patients Global Impression of Change at Week 52", "description": "PGIC (Patient global impression of change) is an overall evaluation of response to treatment, conducted by the patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse).", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Patients Global Impression of Severity at Week 52", "description": "PGI-S (Patient global impression of severity) is an overall evaluation of patient's perception of overall symptom severity using a 6-point rating scale, ranging from 0 = No symptoms, 1=Very mild symptoms, 2=Mild symptoms, 3=Moderate symptoms, 4=Severe symptoms, 5=Very severe symptoms", "timeFrame": "At Study Week 52"}, {"measure": "Mean Change From Baseline at Week 52 in Blood Eosinophils (Cells/uL)", "description": "Mean change from baseline at Study Week 52 in blood eosinophils (cells/uL)", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline at Week 52 in Total Serum IgE (IU/mL)", "description": "Mean change from baseline at Study Week 52 in total serum IgE (IU/mL)", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Number of Participants With Asthma Specific Healthcare Utilization Over 52 Weeks", "description": "Number of participants with asthma specific healthcare utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52 (Weekly Means)", "description": "Mean change from baseline in home based morning PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52 (Weekly Means)", "description": "Mean change from baseline in home based evening PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Mean Change From Baseline in Night Time Awakenings (Weekly Means) at Week 52", "description": "Mean change from baseline in night time awakenings due to asthma at Study Week 52. Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Immunogenecity of Tezepelumab", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post baseline assessments (with \\>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.", "timeFrame": "Baseline, and from time of first dose at Week 0 to end of study at Week 64."}, {"measure": "Proportion of Subjects Who Had no Asthma Exacerbations", "description": "The proportion of subjects who have no exacerbations is presented as the percentage of subjects with no exacerbations. This is defined as subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalisation", "description": "The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF)", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Proportion of Subjects With at Least One Asthma Exacerbation Associated With Emergency Room Visit or Hospitalisation", "description": "Proportion of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation as recorded by the investigator in the CRF. This is presented as percentage of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Proportion of Subjects Who Had no Asthma Exacerbations Associated With Emergency Room or Hospitalisation", "description": "The proportion of subjects with no exacerbations is presented as percentage of subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation associated with emergency room or hospitalisation during this period.", "timeFrame": "From randomisation to Study Week 52"}], "otherOutcomes": [{"measure": "Annual Asthma Exacerbation Rate Associated With Hospitalisations", "description": "The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with hospitalization", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Annual Asthma Exacerbation Rate Using Adjudicated Data", "description": "The annualized exacerbation rate is based on exacerbations as defined for the primary endpoint, but any hospitalisation and ER visits which are adjudicated to be asthma related are added, and those adjudicated to not be asthma related are removed from analyses.", "timeFrame": "From randomisation to Study Week 52"}, {"measure": "Annual Asthma Exacerbation Rate Associated With Emergency Room (ER) Visit or Hospitalisation Using Adjudicated Data", "description": "The annualized exacerbation rate is based on exacerbations associated with hospitalisations or ER visits, where hospitalisation and ER visits adjudicated to be asthma related are added, and those adjudicated to not be asthma related are removed from analyses.", "timeFrame": "From randomisation to Study Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age. 12-80\n* Documented physician-diagnosed asthma for at least 12 months\n* Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months.\n* Documented treatment with a total daily dose of either medium or high dose ICS (\u2265 500 \u00b5g fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.\n* At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.\n* Morning pre-BD FEV1 \\<80% predicted normal (\\<90% for subjects 12-17 yrs)\n* Evidence of asthma as documented by either: Documented historical reversibility of FEV1 \u226512% and \u2265200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol) reversibility of FEV1 \u226512% and \u2265200 mL during screening.\n* Documented history of at least 2 asthma exacerbation events within 12 months.\n* ACQ-6 score \u22651.5 at screening and on day of randomization\n\nExclusion Criteria:\n\n* Pulmonary disease other than asthma.\n* History of cancer.\n* History of a clinically significant infection.\n* Current smokers or subjects with smoking history \u226510 pack-years and subjects using vaping products, including electronic cigarettes.\n* History of chronic alcohol or drug abuse within 12 months.\n* Hepatitis B, C or HIV.\n* Pregnant or breastfeeding.\n* History of anaphylaxis following any biologic therapy.\n* Subject randomized in the current study or previous tezepelumab studies.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "80 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Andrew Menzies-Gow, MD", "affiliation": "Royal Brompton Hospital, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Dothan", "state": "Alabama", "zip": "36303", "country": "United States", "geoPoint": {"lat": 31.22323, "lon": -85.39049}}, {"facility": "Research Site", "city": "Foley", "state": "Alabama", "zip": "36535", "country": "United States", "geoPoint": {"lat": 30.40659, "lon": -87.6836}}, {"facility": "Research Site", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Research Site", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Research Site", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Research Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Research Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Research Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Research Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Research Site", "city": "Northridge", "state": "California", "zip": "91324", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Research Site", "city": "Palm Desert", "state": "California", "zip": "92260", "country": "United States", "geoPoint": {"lat": 33.72255, "lon": -116.37697}}, {"facility": "Research Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Research Site", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Research Site", "city": "Celebration", "state": "Florida", "zip": "34747", "country": "United States", "geoPoint": {"lat": 28.32529, "lon": -81.53313}}, {"facility": "Research Site", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Research Site", "city": "Kissimmee", "state": "Florida", "zip": "34744", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32825", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Panama City", "state": "Florida", "zip": "32405", "country": "United States", "geoPoint": {"lat": 30.15946, "lon": -85.65983}}, {"facility": "Research Site", "city": "Port Charlotte", "state": "Florida", "zip": "33952", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "Research Site", "city": "Saint Petersburg", "state": "Florida", "zip": "33704", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Research Site", "city": "Saint Petersburg", "state": "Florida", "zip": "33710", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Research Site", "city": "Saint Petersburg", "state": "Florida", "zip": "33713", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Research Site", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Research Site", "city": "Sebring", "state": "Florida", "zip": "33870", "country": "United States", "geoPoint": {"lat": 27.49559, "lon": -81.44091}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33607", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Fayetteville", "state": "Georgia", "zip": "30214", "country": "United States", "geoPoint": {"lat": 33.44873, "lon": -84.45493}}, {"facility": "Research Site", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "Stockbridge", "state": "Georgia", "zip": "30281", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Research Site", "city": "Boise", "state": "Idaho", "zip": "83706", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Research Site", "city": "Michigan City", "state": "Indiana", "zip": "46360", "country": "United States", "geoPoint": {"lat": 41.70754, "lon": -86.89503}}, {"facility": "Research Site", "city": "Fort Mitchell", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Research Site", "city": "Louisville", "state": "Kentucky", "zip": "40215", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Research Site", "city": "Lake Charles", "state": "Louisiana", "zip": "70601", "country": "United States", "geoPoint": {"lat": 30.21309, "lon": -93.2044}}, {"facility": "Research Site", "city": "Zachary", "state": "Louisiana", "zip": "70791", "country": "United States", "geoPoint": {"lat": 30.64852, "lon": -91.1565}}, {"facility": "Research Site", "city": "White Marsh", "state": "Maryland", "zip": "21162", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Research Site", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Research Site", "city": "Fall River", "state": "Massachusetts", "zip": "02721", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "Research Site", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Research Site", "city": "Flint", "state": "Michigan", "zip": "48504", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"facility": "Research Site", "city": "Novi", "state": "Michigan", "zip": "48375", "country": "United States", "geoPoint": {"lat": 42.48059, "lon": -83.47549}}, {"facility": "Research Site", "city": "Port Huron", "state": "Michigan", "zip": "48060", "country": "United States", "geoPoint": {"lat": 42.97086, "lon": -82.42491}}, {"facility": "Research Site", "city": "Troy", "state": "Michigan", "zip": "48085", "country": "United States", "geoPoint": {"lat": 42.60559, "lon": -83.14993}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63108", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Lincoln", "state": "Nebraska", "zip": "68505", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "zip": "89106", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "zip": "89119", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Northfield", "state": "New Jersey", "zip": "08225", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Research Site", "city": "Toms River", "state": "New Jersey", "zip": "08755", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10459", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10465", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Brooklyn", "state": "New York", "zip": "11235", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10022", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Valhalla", "state": "New York", "zip": "10595", "country": "United States", "geoPoint": {"lat": 41.07482, "lon": -73.77513}}, {"facility": "Research Site", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Research Site", "city": "Gastonia", "state": "North Carolina", "zip": "28054", "country": "United States", "geoPoint": {"lat": 35.26208, "lon": -81.1873}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27104", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45229", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Mayfield Heights", "state": "Ohio", "zip": "44124", "country": "United States", "geoPoint": {"lat": 41.51922, "lon": -81.4579}}, {"facility": "Research Site", "city": "Toledo", "state": "Ohio", "zip": "43608", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Research Site", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15243", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Warwick", "state": "Rhode Island", "zip": "02886", "country": "United States", "geoPoint": {"lat": 41.7001, "lon": -71.41617}}, {"facility": "Research Site", "city": "Anderson", "state": "South Carolina", "zip": "29621", "country": "United States", "geoPoint": {"lat": 34.50344, "lon": -82.65013}}, {"facility": "Research Site", "city": "Columbia", "state": "South Carolina", "zip": "29204", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "Research Site", "city": "Greenville", "state": "South Carolina", "zip": "29607", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Research Site", "city": "Allen", "state": "Texas", "zip": "75013", "country": "United States", "geoPoint": {"lat": 33.10317, "lon": -96.67055}}, {"facility": "Research Site", "city": "Amarillo", "state": "Texas", "zip": "79106", "country": "United States", "geoPoint": {"lat": 35.222, "lon": -101.8313}}, {"facility": "Research Site", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75225", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Lampasas", "state": "Texas", "zip": "76550", "country": "United States", "geoPoint": {"lat": 31.06378, "lon": -98.1817}}, {"facility": "Research Site", "city": "McAllen", "state": "Texas", "zip": "78504", "country": "United States", "geoPoint": {"lat": 26.20341, "lon": -98.23001}}, {"facility": "Research Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Manassas", "state": "Virginia", "zip": "20110", "country": "United States", "geoPoint": {"lat": 38.75095, "lon": -77.47527}}, {"facility": "Research Site", "city": "Richmond", "state": "Virginia", "zip": "23220", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Research Site", "city": "Richmond", "state": "Virginia", "zip": "23235", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Research Site", "city": "Cudahy", "state": "Wisconsin", "zip": "53110", "country": "United States", "geoPoint": {"lat": 42.95974, "lon": -87.86147}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Buenos Aires", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "zip": "C1056ABJ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "C\u00f3rdoba", "zip": "X5003DCE", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Research Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Nueve de julio", "zip": "B6500EZL", "country": "Argentina", "geoPoint": {"lat": -35.44437, "lon": -60.88313}}, {"facility": "Research Site", "city": "Quilmes", "zip": "B1878FNR", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "Research Site", "city": "Campbelltown", "zip": "2560", "country": "Australia", "geoPoint": {"lat": -34.06667, "lon": 150.81667}}, {"facility": "Research Site", "city": "Kent Town", "zip": "5067", "country": "Australia", "geoPoint": {"lat": -34.92155, "lon": 138.62009}}, {"facility": "Research Site", "city": "Melbourne", "zip": "3004", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "Research Site", "city": "Nedlands", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Research Site", "city": "New Lambton", "zip": "2310", "country": "Australia", "geoPoint": {"lat": -32.95, "lon": 151.68333}}, {"facility": "Research Site", "city": "Spearwood", "zip": "6163", "country": "Australia", "geoPoint": {"lat": -32.10534, "lon": 115.77797}}, {"facility": "Research Site", "city": "Westmead", "zip": "2145", "country": "Australia", "geoPoint": {"lat": -33.80383, "lon": 150.98768}}, {"facility": "Research Site", "city": "Woolloongabba", "zip": "4102", "country": "Australia", "geoPoint": {"lat": -27.48855, "lon": 153.03655}}, {"facility": "Research Site", "city": "Klagenfurt", "zip": "9020", "country": "Austria", "geoPoint": {"lat": 46.62472, "lon": 14.30528}}, {"facility": "Research Site", "city": "Linz", "zip": "4020", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"facility": "Research Site", "city": "Salzburg", "zip": "5020", "country": "Austria", "geoPoint": {"lat": 47.79941, "lon": 13.04399}}, {"facility": "Research Site", "city": "Wien", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Research Site", "city": "Wien", "zip": "1130", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Research Site", "city": "Blumenau", "zip": "89030-101", "country": "Brazil", "geoPoint": {"lat": -26.91944, "lon": -49.06611}}, {"facility": "Research Site", "city": "Botucatu", "zip": "18618-970", "country": "Brazil", "geoPoint": {"lat": -22.88583, "lon": -48.445}}, {"facility": "Research Site", "city": "Curitiba", "zip": "80060-900", "country": "Brazil", "geoPoint": {"lat": -25.42778, "lon": -49.27306}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "9002-060", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "90035-074", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "90610-000", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "90619-900", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "91350-200", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Recife", "zip": "50070-550", "country": "Brazil", "geoPoint": {"lat": -8.05389, "lon": -34.88111}}, {"facility": "Research Site", "city": "Salvador", "zip": "41940-455", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "Research Site", "city": "Santo Andre", "zip": "09080-110", "country": "Brazil", "geoPoint": {"lat": -23.66389, "lon": -46.53833}}, {"facility": "Research Site", "city": "Sao Bernardo do Campo", "zip": "09750-420", "country": "Brazil", "geoPoint": {"lat": -23.69389, "lon": -46.565}}, {"facility": "Research Site", "city": "Sorocaba", "zip": "18040-425", "country": "Brazil", "geoPoint": {"lat": -23.50167, "lon": -47.45806}}, {"facility": "Research Site", "city": "Vit\u00f3ria", "zip": "29055-450", "country": "Brazil", "geoPoint": {"lat": -20.31944, "lon": -40.33778}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Sherwood Park", "state": "Alberta", "zip": "T8L 0N2", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1S 2J5", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Research Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Windsor", "state": "Ontario", "zip": "N8X 1T3", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "St Charles Borromee", "state": "Quebec", "zip": "J6E 2B4", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "Research Site", "city": "Trois-Rivi\u00e8res", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Y8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Brest Cedex", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Research Site", "city": "GRENOBLE Cedex 9", "zip": "38043", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "Research Site", "city": "Le Kremlin Bic\u00eatre", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Research Site", "city": "Lille Cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Research Site", "city": "Lyon Cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Research Site", "city": "MARSEILLE Cedex 20", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier Cedex 5", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Nantes Cedex 1", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Research Site", "city": "PARIS Cedex 12", "zip": "75571", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Paris Cedex 18", "zip": "75877", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Paris", "zip": "75015", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Pessac", "zip": "33604", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"facility": "Research Site", "city": "Strasbourg Cedex", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Research Site", "city": "Toulouse CEDEX 09", "zip": "31059", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "Research Site", "city": "Bamberg", "zip": "96049", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Frankfurt am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Hannover", "zip": "D-30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Landsberg", "zip": "86899", "country": "Germany", "geoPoint": {"lat": 51.52698, "lon": 12.16076}}, {"facility": "Research Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "Leipzig", "zip": "04357", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "L\u00fcbeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Research Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Ashkelon", "zip": "7830604", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"facility": "Research Site", "city": "Haifa", "zip": "34362", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Research Site", "city": "Jerusalem", "zip": "91031", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Research Site", "city": "Jerusalem", "zip": "91120", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Research Site", "city": "Kfar Saba", "zip": "49281", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Research Site", "city": "Rehovot", "zip": "7661041", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Research Site", "city": "Bunkyo-ku", "zip": "113-8431", "country": "Japan", "geoPoint": {"lat": 35.37517, "lon": 139.92991}}, {"facility": "Research Site", "city": "Chuo-ku", "zip": "103-0022", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Chuo-ku", "zip": "103-0028", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Chuo-ku", "zip": "104-0031", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Edogawa-ku", "zip": "134-0083", "country": "Japan"}, {"facility": "Research Site", "city": "Fujieda-shi", "zip": "426-8677", "country": "Japan", "geoPoint": {"lat": 34.86667, "lon": 138.26667}}, {"facility": "Research Site", "city": "Fukuoka-shi", "zip": "810-0001", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Fukuoka-shi", "zip": "811-1394", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Fukuoka-shi", "zip": "815-8588", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Habikino-shi", "zip": "583-8588", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Research Site", "city": "Hamamatsu-shi", "zip": "431-3192", "country": "Japan", "geoPoint": {"lat": 34.7, "lon": 137.73333}}, {"facility": "Research Site", "city": "Higashiibaraki-gun", "zip": "311-3193", "country": "Japan"}, {"facility": "Research Site", "city": "Himeji-shi", "zip": "672-8064", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Research Site", "city": "Hitachi-shi", "zip": "317-0077", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 140.65}}, {"facility": "Research Site", "city": "Itabashi-ku", "zip": "173-0003", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Itabashi-ku", "zip": "173-8610", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Kagoshima-shi", "zip": "890-0073", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Research Site", "city": "Kagoshima-shi", "zip": "890-8520", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Research Site", "city": "Kanazawa-shi", "zip": "920-8530", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Research Site", "city": "Kanazawa-shi", "zip": "920-8641", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Research Site", "city": "Kasuga-shi", "zip": "816-0813", "country": "Japan"}, {"facility": "Research Site", "city": "Kishiwada-shi", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Research Site", "city": "Kitakyusyu", "zip": "802-0052", "country": "Japan"}, {"facility": "Research Site", "city": "Koga-shi", "zip": "811-3195", "country": "Japan", "geoPoint": {"lat": 33.73333, "lon": 130.46667}}, {"facility": "Research Site", "city": "Matsusaka-shi", "zip": "515-8544", "country": "Japan"}, {"facility": "Research Site", "city": "Meguro-ku", "zip": "152-0021", "country": "Japan", "geoPoint": {"lat": 42.12755, "lon": 143.31736}}, {"facility": "Research Site", "city": "Meguro-ku", "zip": "152-8621", "country": "Japan", "geoPoint": {"lat": 42.12755, "lon": 143.31736}}, {"facility": "Research Site", "city": "Minato-ku", "zip": "105-0003", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Research Site", "city": "Minato-ku", "zip": "105-0004", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Research Site", "city": "Minato-ku", "zip": "108-0014", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Research Site", "city": "Mizunami-shi", "zip": "509-6134", "country": "Japan", "geoPoint": {"lat": 35.36667, "lon": 137.25}}, {"facility": "Research Site", "city": "Nagaoka-shi", "zip": "940-2085", "country": "Japan", "geoPoint": {"lat": 37.45, "lon": 138.85}}, {"facility": "Research Site", "city": "Niigata-shi", "zip": "951-8520", "country": "Japan", "geoPoint": {"lat": 37.88637, "lon": 139.00589}}, {"facility": "Research Site", "city": "Ogaki-shi", "zip": "503-8502", "country": "Japan", "geoPoint": {"lat": 35.35, "lon": 136.61667}}, {"facility": "Research Site", "city": "Ohota-ku", "zip": "145-0063", "country": "Japan"}, {"facility": "Research Site", "city": "Omuta-shi", "zip": "837-0911", "country": "Japan", "geoPoint": {"lat": 33.03333, "lon": 130.45}}, {"facility": "Research Site", "city": "Sagamihara-shi", "zip": "228-0815", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Research Site", "city": "Sapporo-shi", "zip": "001-0901", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Research Site", "city": "Sapporo-shi", "zip": "064-0804", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Research Site", "city": "Setagaya-ku", "zip": "157-0072", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Research Site", "city": "Shibuya-ku", "zip": "150-0013", "country": "Japan", "geoPoint": {"lat": 35.469, "lon": 140.29807}}, {"facility": "Research Site", "city": "Shinagawa-ku", "zip": "140-8522", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Research Site", "city": "Shinagawa-ku", "zip": "142-8666", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Research Site", "city": "Shinjuku-ku", "zip": "162-8655", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Research Site", "city": "Shinjuku-ku", "zip": "162-8666", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Research Site", "city": "Sumida-ku", "zip": "130-0015", "country": "Japan"}, {"facility": "Research Site", "city": "Takamatsu-shi", "zip": "761-8073", "country": "Japan", "geoPoint": {"lat": 34.33333, "lon": 134.05}}, {"facility": "Research Site", "city": "Toshima-ku", "zip": "170-0003", "country": "Japan"}, {"facility": "Research Site", "city": "Toshima-ku", "zip": "171-0014", "country": "Japan"}, {"facility": "Research Site", "city": "Ube", "zip": "755-8505", "country": "Japan", "geoPoint": {"lat": 33.94306, "lon": 131.25111}}, {"facility": "Research Site", "city": "Yokkaichi-shi", "zip": "510-8567", "country": "Japan", "geoPoint": {"lat": 34.96667, "lon": 136.61667}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "223-0059", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "236-0004", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "236-0024", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yoshida-gun", "zip": "910-1193", "country": "Japan"}, {"facility": "Research Site", "city": "Bucheon-si", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Cheongju-si", "zip": "28644", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Research Site", "city": "Daegu", "zip": "41404", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Research Site", "city": "Daegu", "zip": "42415", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Research Site", "city": "Jeju-si", "zip": "690-767", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Jeonju-si", "zip": "54907", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Seongnam-si", "zip": "13620", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Research Site", "city": "Seoul", "zip": "02447", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03312", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "05505", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "06351", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "07985", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "150-713", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon-si", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Izhevsk", "zip": "426035", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Research Site", "city": "Moscow", "zip": "115093", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "115522", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "St-Petersburg", "zip": "193231", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Jeddah", "zip": "21423", "country": "Saudi Arabia", "geoPoint": {"lat": 21.54238, "lon": 39.19797}}, {"facility": "Research Site", "city": "Jeddah", "zip": "22252", "country": "Saudi Arabia", "geoPoint": {"lat": 21.54238, "lon": 39.19797}}, {"facility": "Research Site", "city": "Bellville", "zip": "7530", "country": "South Africa", "geoPoint": {"lat": -33.90022, "lon": 18.62847}}, {"facility": "Research Site", "city": "Boksburg North", "zip": "1460", "country": "South Africa", "geoPoint": {"lat": -26.20535, "lon": 28.25392}}, {"facility": "Research Site", "city": "Cape Town", "zip": "7570", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Cape Town", "zip": "7764", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Durban", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Durban", "zip": "4091", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Durban", "zip": "4092", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Durban", "zip": "4450", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Johannesburg", "zip": "1724", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Research Site", "city": "Johannesburg", "zip": "1829", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Research Site", "city": "Johannesburg", "zip": "2113", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Research Site", "city": "Lenasia Ext8", "zip": "1820", "country": "South Africa"}, {"facility": "Research Site", "city": "Middelburg", "zip": "1055", "country": "South Africa", "geoPoint": {"lat": -25.77507, "lon": 29.46482}}, {"facility": "Research Site", "city": "Mowbray", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.94802, "lon": 18.47333}}, {"facility": "Research Site", "city": "Parow", "zip": "7505", "country": "South Africa", "geoPoint": {"lat": -33.89723, "lon": 18.59992}}, {"facility": "Research Site", "city": "Pretoria", "zip": "0157", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Research Site", "city": "Umkomaas", "zip": "4170", "country": "South Africa", "geoPoint": {"lat": -30.20674, "lon": 30.79776}}, {"facility": "Research Site", "city": "Witbank", "zip": "1035", "country": "South Africa", "geoPoint": {"lat": -25.87133, "lon": 29.23323}}, {"facility": "Research Site", "city": "Hsinchu", "zip": "300", "country": "Taiwan", "geoPoint": {"lat": 24.80361, "lon": 120.96861}}, {"facility": "Research Site", "city": "Kaohsiung City", "zip": "82445", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Research Site", "city": "Kaohsiung Hsien", "zip": "TAIWAN", "country": "Taiwan"}, {"facility": "Research Site", "city": "Kaohsiung", "zip": "80756", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Research Site", "city": "Taichung", "zip": "40443", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Research Site", "city": "Tainan City", "zip": "70403", "country": "Taiwan", "geoPoint": {"lat": 22.99083, "lon": 120.21333}}, {"facility": "Research Site", "city": "Taipei", "zip": "220216", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "235", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Yilan", "zip": "260", "country": "Taiwan", "geoPoint": {"lat": 24.757, "lon": 121.753}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kharkiv Region", "zip": "61075", "country": "Ukraine"}, {"facility": "Research Site", "city": "London", "zip": "SW3 6NP", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "Ha Noi", "zip": "100000", "country": "Vietnam", "geoPoint": {"lat": 20.47366, "lon": 106.02292}}, {"facility": "Research Site", "city": "Hanoi", "zip": "100000", "country": "Vietnam", "geoPoint": {"lat": 21.0245, "lon": 105.84117}}, {"facility": "Research Site", "city": "Hanoi", "zip": "10000", "country": "Vietnam", "geoPoint": {"lat": 21.0245, "lon": 105.84117}}, {"facility": "Research Site", "city": "Ho Chi Minh", "zip": "70000", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}]}, "referencesModule": {"references": [{"pmid": "33979488", "type": "DERIVED", "citation": "Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist A, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975."}, {"pmid": "33050934", "type": "DERIVED", "citation": "Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist A, Mo M, Garcia Gil E. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020 Oct 13;21(1):266. doi: 10.1186/s12931-020-01526-6."}], "seeAlsoLinks": [{"label": "Related Info", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00007&amp;attachmentIdentifier=103f6433-96f8-44c4-b837-d7315e83136d&amp;fileName=d5180c00007-csp-v5-14.May.2020_Redacted.pdf&amp;versionIdentifier="}, {"label": "Related Info", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00007&amp;attachmentIdentifier=3d32e500-6365-408d-bdb5-c145f83f1d2b&amp;fileName=d5180c00007-sap-ed-4_22.Oct.2020_Redacted.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 1061 randomised, 1059 (99.8%) subjects received treatment. 82 (7.7%) of the subjects randomised and treated were adolescents.", "recruitmentDetails": "A total of 1061 subjects were randomised at 231 centres in 17 countries to receive treatment with tezepelumab 210mg Q4W or placebo,", "groups": [{"id": "FG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "FG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "529"}, {"groupId": "FG001", "numSubjects": "532"}]}, {"type": "Received Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "528"}, {"groupId": "FG001", "numSubjects": "531"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "513"}, {"groupId": "FG001", "numSubjects": "509"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "23"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Did not receive treatment / Non-compliance with protocol / did not complete safety follow-up visits", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "BG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "528"}, {"groupId": "BG001", "value": "531"}, {"groupId": "BG002", "value": "1059"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "82"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "391"}, {"groupId": "BG001", "value": "416"}, {"groupId": "BG002", "value": "807"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "170"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.9", "spread": "16.3"}, {"groupId": "BG001", "value": "49.0", "spread": "15.9"}, {"groupId": "BG002", "value": "49.5", "spread": "16.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "335"}, {"groupId": "BG001", "value": "337"}, {"groupId": "BG002", "value": "672"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "193"}, {"groupId": "BG001", "value": "194"}, {"groupId": "BG002", "value": "387"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "332"}, {"groupId": "BG001", "value": "327"}, {"groupId": "BG002", "value": "659"}]}]}, {"title": "Black of African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "61"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "146"}, {"groupId": "BG001", "value": "149"}, {"groupId": "BG002", "value": "295"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "42"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "164"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "445"}, {"groupId": "BG001", "value": "450"}, {"groupId": "BG002", "value": "895"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma", "description": "The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per year", "timeFrame": "From randomisation to Study Week 52.", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.93", "lowerLimit": "0.80", "upperLimit": "1.07"}, {"groupId": "OG001", "value": "2.10", "lowerLimit": "1.84", "upperLimit": "2.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Negative Binomial", "paramType": "Rate Ratio", "paramValue": "0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "0.53"}]}, {"type": "PRIMARY", "title": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL", "description": "The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. This analysis is based on subjects with baseline eosinophils \\< 300 cells/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per year", "timeFrame": "From randomisation to Study Week 52.", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "309"}, {"groupId": "OG001", "value": "309"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.02", "lowerLimit": "0.84", "upperLimit": "1.23"}, {"groupId": "OG001", "value": "1.73", "lowerLimit": "1.46", "upperLimit": "2.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Negative Binomial", "paramType": "Rate Ratio", "paramValue": "0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "0.75"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) (L) (Key Secondary Endpoint)", "description": "Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.", "populationDescription": "Number of participants analyzed is the number of subjects with an observation at Week 52. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "471"}, {"groupId": "OG001", "value": "453"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "0.018"}, {"groupId": "OG001", "value": "0.10", "spread": "0.018"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least Squares (LS) Mean Difference", "paramValue": "0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.08", "ciUpperLimit": "0.18"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score (Key Secondary Endpoint)", "description": "Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).", "populationDescription": "Number of participants analyzed is the number of subjects with an observation at Week 52. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scale of score", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "467"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.48", "spread": "0.049"}, {"groupId": "OG001", "value": "1.14", "spread": "0.049"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Means Difference", "paramValue": "0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2", "ciUpperLimit": "0.47"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Asthma Control Questionnaire-6(ACQ-6) (Key Secondary Endpoint)", "description": "Change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting \u03b22-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.", "populationDescription": "Number of participants analyzed is the number of subjects with an observation at Week 52. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scale of score", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "485"}, {"groupId": "OG001", "value": "472"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.53", "spread": "0.045"}, {"groupId": "OG001", "value": "-1.20", "spread": "0.046"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Means Difference", "paramValue": "-0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.46", "ciUpperLimit": "-0.2"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Asthma Symptom Diary (Key Secondary Endpoint)", "description": "Mean change from baseline at Week 52 in Asthma Symptom Diary. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.", "populationDescription": "Number of participants analyzed is the number of subjects with a weekly mean at Week 52. All subjects from the Full Analysis Set with at least one change from baseline weekly mean at any post-baseline week contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scale of score", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "374"}, {"groupId": "OG001", "value": "355"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "0.027"}, {"groupId": "OG001", "value": "-0.59", "spread": "0.027"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Means Difference", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.19", "ciUpperLimit": "-0.04"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation", "description": "Time to first occurrence of asthma exacerbation post-randomisation, presented as number of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "231"}, {"groupId": "OG001", "value": "319"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Clinic Fractional Exhaled Nitric Oxide (FeNO) (Ppb)", "description": "Mean change from baseline at Study Week 52 in FeNO (ppb) measured at site", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ppb", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "440"}, {"groupId": "OG001", "value": "426"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-17.29", "spread": "1.156"}, {"groupId": "OG001", "value": "-3.46", "spread": "1.165"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52", "description": "Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \\[number of night nebulizer times\\] + number of daytime inhaler puffs + 2 x \\[number of day nebulizer times\\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "weekly mean rescue medication use", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "428"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.53", "spread": "0.137"}, {"groupId": "OG001", "value": "-2.36", "spread": "0.137"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Work Productivity Loss Due to Asthma at Week 52", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked.", "populationDescription": "The work productivity loss is only applicable to subjects who were employed, which is a subset of the study population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of work productivity loss", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}, {"groupId": "OG001", "value": "177"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.16", "spread": "30.31"}, {"groupId": "OG001", "value": "-16.58", "spread": "29.46"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Class Productivity Loss Due to Asthma at Week 52", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Class productivity loss is derived by sum of percentage of missed class hours due to asthma and product of percentage of actual hours in class times degree of asthma affecting productivity while in class. Percentage of missed hours in class due to asthma is calculated by number of hours in class missed due to asthma divided by total number of hours in class missed plus number of hours actually in class.", "populationDescription": "The class productivity loss is only applicable to subjects attending school, which is a subset of the study population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of class productivity loss", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.03", "spread": "33.00"}, {"groupId": "OG001", "value": "-24.72", "spread": "26.48"}]}]}]}, {"type": "SECONDARY", "title": "Activity Impairment at Week 52", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Activity impairment is the degree health affected regular activities (other than work or class) rated from 0 to 10, with 0 meaning no effect, divided by 10, and then expressed as a percentage.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of activity impairment", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "401"}, {"groupId": "OG001", "value": "393"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.0", "spread": "28.6"}, {"groupId": "OG001", "value": "-17.9", "spread": "27.1"}]}]}]}, {"type": "SECONDARY", "title": "Pharmacokinetics of Tezepelumab", "description": "Mean serum trough PK concentrations taken pre-dose at each visit", "populationDescription": "Number of subjects who received at least one dose of IP. Number analysed at each timepoint is a subset of this based on subjects who had sample results available at that timepoint. The placebo arm is not applicable since it is not the experimental product.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ug/mL", "timeFrame": "Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, Week 64", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "524"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "0"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "514"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.1573", "spread": "74.51"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "491"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.7396", "spread": "48.53"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "461"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.1924", "spread": "51.77"}]}]}, {"title": "Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "464"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.5246", "spread": "55.58"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "452"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.8894", "spread": "70.04"}]}]}, {"title": "Week 64", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7675", "spread": "171.86"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in EQ-5D-5L VAS", "description": "Mean change from baseline at Study Week 52 in EQ-5D-5L VAS. EQ-5D-5L visual analogue scale (VAS) allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scale of score", "timeFrame": "At Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "435"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.64", "spread": "0.708"}, {"groupId": "OG001", "value": "11.86", "spread": "0.712"}]}]}]}, {"type": "SECONDARY", "title": "Clinicians Global Impression of Change at Week 52", "description": "CGIC (Clinical global impression of change) is an overall evaluation of response to treatment, conducted by investigator using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse)", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "483"}, {"groupId": "OG001", "value": "477"}]}], "classes": [{"categories": [{"title": "Very much improved", "measurements": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "60"}]}, {"title": "Much improved", "measurements": [{"groupId": "OG000", "value": "199"}, {"groupId": "OG001", "value": "132"}]}, {"title": "Minimally improved", "measurements": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "131"}]}, {"title": "No change", "measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "130"}]}, {"title": "Minimally worse", "measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "19"}]}, {"title": "Much worse", "measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}, {"title": "Very much worse", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Patients Global Impression of Change at Week 52", "description": "PGIC (Patient global impression of change) is an overall evaluation of response to treatment, conducted by the patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse).", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "479"}, {"groupId": "OG001", "value": "466"}]}], "classes": [{"categories": [{"title": "Very much improved", "measurements": [{"groupId": "OG000", "value": "255"}, {"groupId": "OG001", "value": "182"}]}, {"title": "Much Improved", "measurements": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "94"}]}, {"title": "Minimally improved", "measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "76"}]}, {"title": "No change", "measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "99"}]}, {"title": "Minimally worse", "measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}]}, {"title": "Much worse", "measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}, {"title": "Very much worse", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Patients Global Impression of Severity at Week 52", "description": "PGI-S (Patient global impression of severity) is an overall evaluation of patient's perception of overall symptom severity using a 6-point rating scale, ranging from 0 = No symptoms, 1=Very mild symptoms, 2=Mild symptoms, 3=Moderate symptoms, 4=Severe symptoms, 5=Very severe symptoms", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "At Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "479"}, {"groupId": "OG001", "value": "466"}]}], "classes": [{"categories": [{"title": "No symptoms", "measurements": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "78"}]}, {"title": "Very mild symptoms", "measurements": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "128"}]}, {"title": "Mild symptoms", "measurements": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "128"}]}, {"title": "Moderate symptoms", "measurements": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "111"}]}, {"title": "Severe symptoms", "measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "19"}]}, {"title": "Very severe symptoms", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Blood Eosinophils (Cells/uL)", "description": "Mean change from baseline at Study Week 52 in blood eosinophils (cells/uL)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cells/uL", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "458"}, {"groupId": "OG001", "value": "451"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-170.02", "spread": "9.222"}, {"groupId": "OG001", "value": "-40.15", "spread": "9.254"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline at Week 52 in Total Serum IgE (IU/mL)", "description": "Mean change from baseline at Study Week 52 in total serum IgE (IU/mL)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "IU/mL", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "482"}, {"groupId": "OG001", "value": "471"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-164.38", "spread": "34.414"}, {"groupId": "OG001", "value": "43.61", "spread": "34.542"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Asthma Specific Healthcare Utilization Over 52 Weeks", "description": "Number of participants with asthma specific healthcare utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"title": "Hospitalisation", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "37"}]}]}, {"title": "Emergency Room visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "50"}]}]}, {"title": "Unscheduled visit to specialist", "categories": [{"measurements": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "231"}]}]}, {"title": "Home visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Telephone call", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "133"}]}]}, {"title": "Ambulance transport", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52 (Weekly Means)", "description": "Mean change from baseline in home based morning PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "414"}, {"groupId": "OG001", "value": "391"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.57", "spread": "3.051"}, {"groupId": "OG001", "value": "18.01", "spread": "3.074"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52 (Weekly Means)", "description": "Mean change from baseline in home based evening PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "405"}, {"groupId": "OG001", "value": "390"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.87", "spread": "3.075"}, {"groupId": "OG001", "value": "9.01", "spread": "3.094"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Night Time Awakenings (Weekly Means) at Week 52", "description": "Mean change from baseline in night time awakenings due to asthma at Study Week 52. Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of nights with awakenings", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "418"}, {"groupId": "OG001", "value": "395"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.51", "spread": "1.381"}, {"groupId": "OG001", "value": "-30.22", "spread": "1.387"}]}]}]}, {"type": "SECONDARY", "title": "Immunogenecity of Tezepelumab", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post baseline assessments (with \\>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline, and from time of first dose at Week 0 to end of study at Week 64.", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "527"}, {"groupId": "OG001", "value": "530"}]}], "classes": [{"title": "ADA positive at baseline and/or post-baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "44"}]}]}, {"title": "Any baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Only baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Any post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Both baseline and >= 1 post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Treatment induced ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Treatment boosted ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Treatment emergent ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "ADA persistently positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "ADA transiently positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "18"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects Who Had no Asthma Exacerbations", "description": "The proportion of subjects who have no exacerbations is presented as the percentage of subjects with no exacerbations. This is defined as subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.2"}, {"groupId": "OG001", "value": "38.6"}]}]}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalisation", "description": "The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per year", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.04", "upperLimit": "0.09"}, {"groupId": "OG001", "value": "0.28", "lowerLimit": "0.20", "upperLimit": "0.39"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects With at Least One Asthma Exacerbation Associated With Emergency Room Visit or Hospitalisation", "description": "Proportion of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation as recorded by the investigator in the CRF. This is presented as percentage of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.7"}, {"groupId": "OG001", "value": "12.2"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects Who Had no Asthma Exacerbations Associated With Emergency Room or Hospitalisation", "description": "The proportion of subjects with no exacerbations is presented as percentage of subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation associated with emergency room or hospitalisation during this period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92.4"}, {"groupId": "OG001", "value": "85.1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Annual Asthma Exacerbation Rate Associated With Hospitalisations", "description": "The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with hospitalization", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per year", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "lowerLimit": "0.01", "upperLimit": "0.06"}, {"groupId": "OG001", "value": "0.19", "lowerLimit": "0.12", "upperLimit": "0.30"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Annual Asthma Exacerbation Rate Using Adjudicated Data", "description": "The annualized exacerbation rate is based on exacerbations as defined for the primary endpoint, but any hospitalisation and ER visits which are adjudicated to be asthma related are added, and those adjudicated to not be asthma related are removed from analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per year", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "lowerLimit": "0.81", "upperLimit": "1.09"}, {"groupId": "OG001", "value": "2.14", "lowerLimit": "1.88", "upperLimit": "2.44"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Annual Asthma Exacerbation Rate Associated With Emergency Room (ER) Visit or Hospitalisation Using Adjudicated Data", "description": "The annualized exacerbation rate is based on exacerbations associated with hospitalisations or ER visits, where hospitalisation and ER visits adjudicated to be asthma related are added, and those adjudicated to not be asthma related are removed from analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per year", "timeFrame": "From randomisation to Study Week 52", "groups": [{"id": "OG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "lowerLimit": "0.05", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.31", "lowerLimit": "0.22", "upperLimit": "0.42"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "From first dose of study drug until end of study at Week 64.", "eventGroups": [{"id": "EG000", "title": "Tezepelumab 210mg Q4W", "description": "Tezepelumab administered every 4 weeks subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 528, "seriousNumAffected": 52, "seriousNumAtRisk": 528, "otherNumAffected": 306, "otherNumAtRisk": 528}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered subcutaneously", "deathsNumAffected": 2, "deathsNumAtRisk": 531, "seriousNumAffected": 73, "seriousNumAtRisk": 531, "otherNumAffected": 331, "otherNumAtRisk": 531}], "seriousEvents": [{"term": "Aortic valve stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Coronary artery occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Hypertrophic cardiomyopathy", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Uveitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Colitis ischaemic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Diverticular perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Obstruction gastric", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Oesophageal achalasia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Pancreatitis necrotising", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Rectal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Atypical pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Breast abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}]}, {"term": "Gastroenteritis salmonella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Herpes zoster oticus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Lower respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 531}]}, {"term": "Lung abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}]}, {"term": "Pneumonia klebsiella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Pneumonia streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Pneumonia viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Ulna fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Type 1 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Bone cyst", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Myositis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Polyarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}]}, {"term": "Benign neoplasm of thyroid gland", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Colon adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Malignant melanoma in situ", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Squamous cell carcinoma of the oral cavity", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Cubital tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Idiopathic generalised epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Myelopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Ureterolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 14, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 81, "numAffected": 39, "numAtRisk": 531}]}, {"term": "Eosinophilic pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Cyanosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Covid-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}, {"term": "Muscle necrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}]}, {"term": "Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 531}]}], "otherEvents": [{"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 26, "numAffected": 24, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 20, "numAffected": 17, "numAtRisk": 531}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 22, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 24, "numAffected": 22, "numAtRisk": 531}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 17, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 18, "numAffected": 13, "numAtRisk": 531}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 19, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 26, "numAffected": 22, "numAtRisk": 531}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 39, "numAffected": 25, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 36, "numAffected": 33, "numAtRisk": 531}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 17, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 15, "numAffected": 14, "numAtRisk": 531}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 172, "numAffected": 113, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 188, "numAffected": 114, "numAtRisk": 531}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 17, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 17, "numAffected": 15, "numAtRisk": 531}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 14, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 37, "numAffected": 17, "numAtRisk": 531}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 19, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 56, "numAffected": 40, "numAtRisk": 531}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 94, "numAffected": 58, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 129, "numAffected": 88, "numAtRisk": 531}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 20, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 531}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 26, "numAffected": 21, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 16, "numAffected": 15, "numAtRisk": 531}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 96, "numAffected": 43, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 68, "numAffected": 45, "numAtRisk": 531}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 14, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 25, "numAffected": 23, "numAtRisk": 531}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 16, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 25, "numAffected": 17, "numAtRisk": 531}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 23, "numAtRisk": 528}, {"groupId": "EG001", "numEvents": 29, "numAffected": 22, "numAtRisk": 531}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Head", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "+1 302 885 1180"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-05-14", "uploadDate": "2021-10-29T15:10", "filename": "Prot_002.pdf", "size": 1851321}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-10-22", "uploadDate": "2021-10-29T15:10", "filename": "SAP_003.pdf", "size": 1290877}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-10-05", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000911", "term": "Antibodies, Monoclonal"}], "ancestors": [{"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "asFound": "Acceleration", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}